0001140361-17-037024.txt : 20170929
0001140361-17-037024.hdr.sgml : 20170929
20170929201742
ACCESSION NUMBER: 0001140361-17-037024
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170927
FILED AS OF DATE: 20170929
DATE AS OF CHANGE: 20170929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Resnick Joshua
CENTRAL INDEX KEY: 0001690959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 171112898
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: 201 WASHINGTON STREET, SUITE 3900
CITY: BOSTON
STATE: MA
ZIP: 02108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 200, STE. 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 200, STE. 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
doc1.xml
FORM 4
X0306
4
2017-09-27
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001690959
Resnick Joshua
ONE BOSTON PLACE, SUITE 3900
201 WASHINGTON STREET, SUITE 3900
BOSTON
MA
02108
1
0
0
0
Director Stock Option (Right to Buy)
6.71
2017-09-27
4
A
0
6000
0
A
2027-09-26
Common Stock
6000
6000
D
The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.
The option is held by the reporting person for the benefit of SV Health Investors, LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/Benjamin Palleiko, Attorney-in-Fact
2017-09-29